The Journal of Medical Investigation
Online ISSN : 1349-6867
Print ISSN : 1343-1420
ISSN-L : 1343-1420
Originals
Can Kampo therapy prolong the life of cancer patients?
Yoshihiro TakegawaHitoshi IkushimaKyousuke OzakiShunsuke FurutaniTakashi KawanakaTakaharu KudohMasafumi Harada
Author information
JOURNAL FREE ACCESS

2008 Volume 55 Issue 1,2 Pages 99-105

Details
Article 1st page
Abstract

Our policy regarding the performance of radiotherapy to squamous cell carcinoma of the uterine cervix has not changed since 1969. We have already reported the treatment results which were as good as those from other institutions. Since 1978, Kampo therapy was first introduced in the treatment of cancer patients in dealing with problems such as the side effects of radiotherapy and chemotherapy and various types of general malaise. We analyzed our treatment results in order to re-evaluate the chemo-radiotherapy in combination with Kampo. Survival rates for 5, 10 and 15 years, respectively, were 90.9%, 71.6% and 71.6% for Stage IB, 78.9%, 61.8% and 41.8% for Stage II, 62.3%, 49.1% and 41.2% for Stage III and 53.1%, 36.5% and 16.7% for Stage IV.
The Kampo significantly extended the survival of patients with uterine cervical cancer. We intend to perform further research with more patients to explore how this therapy contributes to the prolonging of patients survival. J. Med. Invest. 55: 99-105, February, 2008

Content from these authors
© 2008 by The University of Tokushima Faculty of Medicine
Previous article Next article
feedback
Top